Jounce Therapeutics (JNCE) Insider Sells $113,897.70 in Stock

Jounce Therapeutics (NASDAQ:JNCE) insider Elizabeth Trehu sold 4,545 shares of Jounce Therapeutics stock in a transaction that occurred on Thursday, March 8th. The stock was sold at an average price of $25.06, for a total transaction of $113,897.70. Following the completion of the sale, the insider now owns 4,545 shares of the company’s stock, valued at $113,897.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Elizabeth Trehu also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Monday, March 5th, Elizabeth Trehu sold 4,545 shares of Jounce Therapeutics stock. The stock was sold at an average price of $21.50, for a total transaction of $97,717.50.

NASDAQ JNCE traded down $1.23 during trading hours on Friday, hitting $18.48. 372,089 shares of the company’s stock traded hands, compared to its average volume of 340,821. The firm has a market capitalization of $619.00, a price-to-earnings ratio of -31.54 and a beta of 6.33. Jounce Therapeutics has a 52 week low of $11.05 and a 52 week high of $29.29.

Jounce Therapeutics (NASDAQ:JNCE) last announced its earnings results on Thursday, March 8th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.25. The company had revenue of $13.00 million during the quarter, compared to analyst estimates of $14.95 million. Jounce Therapeutics had a negative net margin of 22.76% and a negative return on equity of 10.24%. The firm’s quarterly revenue was down 36.0% compared to the same quarter last year. During the same period in the previous year, the business posted $0.05 earnings per share. analysts predict that Jounce Therapeutics will post -1.04 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Teachers Advisors LLC lifted its holdings in Jounce Therapeutics by 26.4% during the second quarter. Teachers Advisors LLC now owns 11,231 shares of the company’s stock valued at $158,000 after purchasing an additional 2,347 shares in the last quarter. Alps Advisors Inc. lifted its holdings in Jounce Therapeutics by 12.5% during the fourth quarter. Alps Advisors Inc. now owns 35,642 shares of the company’s stock valued at $454,000 after purchasing an additional 3,966 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Jounce Therapeutics by 10.8% during the fourth quarter. Bank of New York Mellon Corp now owns 45,889 shares of the company’s stock valued at $585,000 after purchasing an additional 4,467 shares in the last quarter. American International Group Inc. lifted its holdings in Jounce Therapeutics by 132.2% during the third quarter. American International Group Inc. now owns 9,559 shares of the company’s stock valued at $149,000 after purchasing an additional 5,442 shares in the last quarter. Finally, OxFORD Asset Management LLP lifted its holdings in Jounce Therapeutics by 11.9% during the third quarter. OxFORD Asset Management LLP now owns 59,540 shares of the company’s stock valued at $927,000 after purchasing an additional 6,328 shares in the last quarter. Institutional investors own 90.30% of the company’s stock.

JNCE has been the subject of several recent research reports. Zacks Investment Research lowered shares of Jounce Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 17th. Robert W. Baird set a $35.00 target price on shares of Jounce Therapeutics and gave the company a “buy” rating in a research report on Thursday, March 8th.

COPYRIGHT VIOLATION NOTICE: “Jounce Therapeutics (JNCE) Insider Sells $113,897.70 in Stock” was posted by BBNS and is owned by of BBNS. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://baseballnewssource.com/2018/04/06/jounce-therapeutics-inc-jnce-insider-sells-113897-70-in-stock/2037786.html.

Jounce Therapeutics Company Profile

Jounce Therapeutics, Inc, a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform.

Insider Buying and Selling by Quarter for Jounce Therapeutics (NASDAQ:JNCE)

Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Andujar, Stanton and Torres Shine in Yankees Rout
Andujar, Stanton and Torres Shine in Yankees Rout
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Red Sox Tie Record for Best Start After 17 Games
Red Sox Tie Record for Best Start After 17 Games
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Rick Porcello’s Strong Start Gives Boost to Red Sox
Rick Porcello’s Strong Start Gives Boost to Red Sox
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry


Leave a Reply

 
© 2006-2018 BBNS.